[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-459994-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-459994-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","transcatheter-aortic-valve-replacement-for-aortic-insufficiency","Transcatheter Aortic Valve Replacement for Aortic Insufficiency","","Transcatheter aortic valve replacement (TAVR) has emerged as a viable treatment for aortic regurgitation (AR), especially in high-risk or elderly patients who cannot undergo surgery. Early devices suffered from high mortality, residual paravalvular leaks, and complications including valve embolisation. Technological progress with self-expanding and balloon-expandable systems improved outcomes, while AR-dedicated devices such as the Trilogy and J-Valve showed better performance and survival. Other candidates may benefit complex, non-calcified or infectious cases, supporting individualized strategies based on anatomy and pathology.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/transcatheter-aortic-valve-replacement-for-aortic-insufficiency/459994/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/transcatheter-aortic-valve-replacement-for-aortic-insufficiency/459994.png","ImageObject",300,407,{"name":42,"@type":43},"Marglet","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is TAVR challenging in pure aortic regurgitation compared with calcific aortic stenosis?","Question",{"text":63,"@type":64},"Pure AR usually lacks valvular calcification, which reduces anchoring stability. It also involves higher stroke volume and a dynamic regurgitant jet that can hinder precise valve deployment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What problems affected early-generation TAVR devices for aortic regurgitation?",{"text":68,"@type":64},"Early devices were associated with high mortality and residual paravalvular leaks, along with complications such as valve embolisation and the need for second valve implantation or a pacemaker.",{"name":70,"@type":61,"acceptedAnswer":71},"How do dedicated AR devices differ from non-dedicated approaches?",{"text":72,"@type":64},"Dedicated systems such as the Trilogy and J-Valve were specifically designed for AR and demonstrated improved performance, with fewer complications and better patient survival in the reported evidence.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},459994,1790794127,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":4},2336477982702,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Transcatheter Aortic Valve Replacement for Aortic Insufficiency  \nMarwan Amara 1,2 and Yair Feld 2  \n1. Cardiology Department, The Baruch Padeh Medical Center (Tzafon), Poriya, Tabarīya, Israel; 2. Cuspa Ltd, Caesarea, Israel  \nAbstract  \nTranscatheter aortic valve replacement (TAVR) has developed into a viable treatment for aortic regurgitation (AR), particularly in high-risk or elderly patients unable to undergo surgery. Early generation devices encountered significant challenges, including high mortality rates, residual paravalvular leaks, and complications such as valve embolisation. However, advancements in TAVR technology, including self-expanding and balloon-expandable devices, have improved procedural outcomes. Dedicated devices, such as the Trilogy system (JenaValve) and J-Valve (Edwards Lifesciences), specifically designed for AR, have demonstrated superior performance with reduced complications and better patient survival. Other devices, such as Cusper (Cuspa) and the Zeta/Alpha systems (Laguna Tech), show potential for treating complex AR cases, including those with non-calcified valves or active endocarditis. These innovations offer hope for patients with severe AR, highlighting the need for tailored approaches based on individual anatomical and pathological variations.  \nKeywords  \nAortic regurgitation, transcatheter aortic valve replacement, dedicated devices  \nReceived: 15 February 2025 Accepted: 7 October 2025 Citation: Interventional Cardiology 2025;20:e36 . DOI: [https://doi.org/10.15420/icr.2025.06](https://doi.org/10.15420/icr.2025.06)  \n[Disclosure:](Disclosure: YF is the founder and director of Cuspa)[ YF is the founder and director of Cuspa](Disclosure: YF is the founder and director of Cuspa), Paragate Medical and HVT Medical. MA has no conflicts of interest to declare.  \nAcknowledgements: The authors used an AI language model for assistance with drafting the introduction and summarising key findings. The final content reflects the authors’ own analysis and interpretations.  \nCorrespondence: Marwan Amara, Cardiology Department, The Baruch Padeh Medical Center (Tzafon), Poriya: Tabarīya, 1528001, [Israel. E: marwan77@hotmail.it](Israel. E: marwan77@hotmail.it)  \nCopyright: © The Author(s) 2025. This work is open access and is licensed under CC-BY-NC 4.0. Users may copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.  \nAortic regurgitation (AR) is a common clinical issue among adults. In individuals above the age of 70 years the prevalence of at least moderate AR is estimated to be about 2. 2% .1 It is identified by the backward flow of blood from the aorta into the left ventricle (LV) during diastole due tomisaligned aortic cusps.2  \nAlthough surgical aortic valve replacement (SAVR) is the recommended treatment of AR, many elderly patients are refused surgery due to high operative risk. However, if left untreated, severe aortic insufficiency with noticeable symptoms carries a high risk of death.3 Studies have shown that more than 70% of individuals with severe symptoms, categorised as New York Heart Association (NYHA) class III or IV, may not survive beyond 5 years.4,5  \nIn response to this identified need and drawing on the successful use of transcatheter aortic valve replacement (TAVR) in aortic stenosis (AS), over the past decade clinicians have been examining the potential of TAVR for AR treatment.  \nThese studies began with early generation TAVR – CoreValve (Medtronic) and the SAPIEN valve (Edwards Lifesciences)– and demonstrated poor outcomes with high mortality, residual paravalvular leak (PVL), second valve implantation, device embolisation and the need for a pacemaker.6–9 These challenges and limitations occurred due to a lack of calcium, difficulty anchoring and root dilatation with large stroke volume causing malpositioning of the prosthesis and embolisation.10–13 The next generation of TAVR with self-expandable and balloon-e","cbCaifA4rMArvlww","https://ap.wps.com/l/cbCaifA4rMArvlww","pdf",6171109,"English","# Abstract\n# Challenges of Transcatheter Aortic Valve Replacement in Pure Aortic Regurgitation\n## Non-dedicated Devices","[{\"question\":\"Why is TAVR challenging in pure aortic regurgitation compared with calcific aortic stenosis?\",\"answer\":\"Pure AR usually lacks valvular calcification, which reduces anchoring stability. It also involves higher stroke volume and a dynamic regurgitant jet that can hinder precise valve deployment.\"},{\"question\":\"What problems affected early-generation TAVR devices for aortic regurgitation?\",\"answer\":\"Early devices were associated with high mortality and residual paravalvular leaks, along with complications such as valve embolisation and the need for second valve implantation or a pacemaker.\"},{\"question\":\"How do dedicated AR devices differ from non-dedicated approaches?\",\"answer\":\"Dedicated systems such as the Trilogy and J-Valve were specifically designed for AR and demonstrated improved performance, with fewer complications and better patient survival in the reported evidence.\"}]","Transcatheter Aortic Valve Replacement for Aortic Insufficiency | PDF",1790757450]